MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
July 29, 2021 16:01 ET
|
MacroGenics, Inc.
Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) MeetingConference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md.,...
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
December 06, 2020 13:00 ET
|
MacroGenics, Inc.
31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patientsMedian duration of response = 8.13 months ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc....
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
November 04, 2020 14:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Flotetuzumab Publication in Blood Advances
October 15, 2020 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 15, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
September 22, 2020 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...